Fuller & Thaler Asset Management Inc. Has $100.41 Million Stake in Doximity, Inc. $DOCS

Key Points

• Fuller & Thaler Asset Management Inc. raised its stake in Doximity, Inc. by 9.5%, owning approximately 1.73 million shares worth $100.4 million as of the latest SEC filing.
• Doximity's shares have seen significant interest from investors, with hedge funds and other institutional investors owning about 87.19% of the company's stock.
• The company reported $0.36 earnings per share for its latest quarter, surpassing analysts' expectations by $0.05 and marking a 15.2% revenue increase year-over-year.

Fuller & Thaler Asset Management Inc. grew its stake in Doximity, Inc. (NASDAQ:DOCS - Free Report) by 9.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,730,282 shares of the company's stock after purchasing an additional 150,574 shares during the quarter. Fuller & Thaler Asset Management Inc. owned about 0.93% of Doximity worth $100,408,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Envestnet Asset Management Inc. increased its position in shares of Doximity by 19.9% in the 4th quarter. Envestnet Asset Management Inc. now owns 162,905 shares of the company's stock valued at $8,697,000 after buying an additional 27,001 shares in the last quarter. Sterling Capital Management LLC increased its position in shares of Doximity by 57.9% in the 4th quarter. Sterling Capital Management LLC now owns 6,929 shares of the company's stock valued at $370,000 after buying an additional 2,542 shares in the last quarter. Townsquare Capital LLC bought a new stake in shares of Doximity in the 4th quarter valued at $220,000. Barclays PLC increased its position in shares of Doximity by 191.1% in the 4th quarter. Barclays PLC now owns 155,447 shares of the company's stock valued at $8,299,000 after buying an additional 102,046 shares in the last quarter. Finally, Mariner LLC increased its position in shares of Doximity by 27.5% in the 4th quarter. Mariner LLC now owns 31,309 shares of the company's stock valued at $1,672,000 after buying an additional 6,753 shares in the last quarter. Institutional investors and hedge funds own 87.19% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on DOCS shares. Truist Financial increased their target price on Doximity from $52.00 to $61.00 and gave the stock a "hold" rating in a report on Thursday, July 17th. The Goldman Sachs Group set a $50.00 target price on Doximity and gave the stock a "neutral" rating in a report on Wednesday, May 21st. BTIG Research upgraded Doximity from a "neutral" rating to a "buy" rating and set a $80.00 target price for the company in a report on Monday, June 2nd. Raymond James Financial increased their target price on Doximity from $65.00 to $75.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Finally, Wells Fargo & Company increased their target price on Doximity from $55.00 to $62.00 and gave the stock an "equal weight" rating in a report on Monday, August 4th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and eleven have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $66.21.

Doximity Trading Up 5.6%

Shares of Doximity stock traded up $3.5630 during trading hours on Friday, reaching $67.6930. 1,637,248 shares of the company's stock were exchanged, compared to its average volume of 2,323,116. The company has a 50 day moving average of $60.80 and a two-hundred day moving average of $60.46. Doximity, Inc. has a fifty-two week low of $35.32 and a fifty-two week high of $85.21. The stock has a market cap of $12.68 billion, a P/E ratio of 67.69, a P/E/G ratio of 4.10 and a beta of 1.36.

Doximity (NASDAQ:DOCS - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.05. Doximity had a net margin of 36.60% and a return on equity of 21.75%. During the same period in the prior year, the company posted $0.28 earnings per share. Doximity's revenue for the quarter was up 15.2% on a year-over-year basis. Doximity has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. As a group, analysts expect that Doximity, Inc. will post 0.99 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Timothy S. Cabral sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, June 25th. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00. Following the transaction, the director directly owned 6,360 shares of the company's stock, valued at approximately $381,600. This trade represents a 61.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kira Scherer Wampler sold 2,000 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $57.09, for a total transaction of $114,180.00. Following the transaction, the director directly owned 16,618 shares in the company, valued at $948,721.62. This represents a 10.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,000 shares of company stock worth $2,140,940 over the last three months. Insiders own 31.30% of the company's stock.

Doximity Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.